| Title | Intervention |
NCT ID |
Sponsor | Status |
|---|---|---|---|---|
| S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and... | therapeutic conventional surgery, gastrointestinal complications management/prevention, quality-of-life assessment | NCT02270450 | Southwest Oncology Group | Active, not recruiting |
| Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Erlotinib | NCT02273362 | National Cancer Institute (NCI) | Active, not recruiting |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast... | Endocrine therapy interruption | NCT02308085 | International Breast Cancer Study Group | Active, not recruiting |
| Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | Telapristone Acetate, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration | NCT02314156 | Northwestern University | Active, not recruiting |
| PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer... | Laboratory Biomarker Analysis, Rilimogene Galvacirepvec, Placebo Administration | NCT02326805 | National Cancer Institute (NCI) | Active, not recruiting |
| MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ | Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Therapeutic Surgical Procedure, Radiation Therapy, Endocrine Therapy, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Cytology Specimen Collection Procedure | NCT02352883 | ECOG-ACRIN Cancer Research Group | Active, not recruiting |
| Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After... | bevacizumab, corticosteroids, placebo | NCT02490878 | Alliance for Clinical Trials in Oncology | Active, not recruiting |
| Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful... | Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration | NCT02521285 | National Cancer Institute (NCI) | Active, not recruiting |
| Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger... | Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine | NCT02568566 | National Cancer Institute (NCI) | Active, not recruiting |
| Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion | Laboratory Biomarker Analysis, Metformin Hydrochloride | NCT02581137 | National Cancer Institute (NCI) | Active, not recruiting |
Why I Joined a Clinical Trial
I was the first patient who Dr. Abraham enrolled on the NSABP B-31 clinical trial (chemo vs chemo + Trastuzumab in HER-2 positive breast cancer). I am grateful to him for presenting me with the opportunity to join the study 20 years ago in March 2001 and that I had the courage to participate, as I continue to do well to this day. This clinical trial ended up changing the landscape of treatment for future patients with breast cancer.